Cubicin — HCPCS J0878 · Daptomycin

About daptomycin (Cubicin) FDA label verified Jul 2026

Daptomycin is a cyclic lipopeptide antibiotic that works by binding to the bacterial cell membrane in a calcium-dependent manner, causing rapid depolarization and cell death — a mechanism distinct from the cell-wall-active glycopeptides (vancomycin) and lipoglycopeptides (dalbavancin, oritavancin). It is bactericidal against gram-positive organisms including MRSA, MSSA, and vancomycin-resistant Enterococcus (VRE), and it is dosed once daily by weight, which makes it one of the most practical IV antibiotics for outpatient parenteral antibiotic therapy (OPAT): a single daily infusion or even a 2-minute IV push, versus multiple-times-daily dosing for many comparators.

Originally developed and marketed by Cubist (later Merck) as Cubicin and the ready-to-use Cubicin RF, the molecule has been off patent for years and is now supplied almost entirely by generic manufacturers — Hikma, Accord, Sagent, Dr. Reddy’s, Apotex, Viatris, and others all currently appear in the CMS ASP pricing file, while Merck’s branded NDCs do not. This matters for billers in two ways: first, most — but not all — NDCs bill J0878: CMS maintains live manufacturer-specific daptomycin codes (J0877 Hospira/Pfizer, J0872/J0873 Xellia, J0874 Baxter) that are not therapeutically equivalent to J0878, so the J-code must be matched to the NDC actually purchased; second, there is no manufacturer copay program to route patients to — the drug is inexpensive enough on ASP that the cost conversation is almost a non-issue compared to most specialty infusibles on this site.

From a billing standpoint, three features drive daptomycin claim accuracy. First, dosing is weight-based and indication-specific — 4 mg/kg for skin/skin-structure infections versus 6 mg/kg for bloodstream infections and endocarditis, calculated on actual body weight, not adjusted or ideal weight. Second, it ships only in 350 mg and 500 mg single-dose vials, so almost every non-round dose leaves some drug to discard-report with JW. Third, the label carries a weekly CPK monitoring requirement for skeletal-muscle toxicity — documentation payers expect to see on any extended OPAT course, particularly one billed off-label at higher mg/kg.

One hard clinical and coverage limit belongs at the top of any daptomycin reference: it is not effective for pneumonia of any kind. Pulmonary surfactant binds and inactivates the drug, so it under-performs in lung tissue regardless of the organism’s in-vitro susceptibility. A pneumonia-coded claim paired with J0878 is a clinical-appropriateness and medical-necessity flag, not a coding nuance.

The daptomycin J-code map — most NDCs bill J0878, but not all CMS HCPCS aligned Jul 2026

Daptomycin has no biosimilar codes (it's a small-molecule generic), but CMS maintains live manufacturer-specific J-codes that are NOT therapeutically equivalent to J0878. Match the code to the NDC actually purchased.

Daptomycin has no biosimilar pathway because it is a chemically synthesized small molecule, not a biologic — but that does not mean one J-code covers everything. Brand Cubicin/Cubicin RF and the ANDA generics (Hikma, Accord, Sagent, Dr. Reddy’s, Apotex, Viatris, NorthStar Rx, and others) bill J0878, while CMS has assigned separate, currently priced manufacturer-specific codes to the Hospira/Pfizer, Xellia, and Baxter daptomycin products. These codes are not therapeutically equivalent to J0878 for billing purposes and carry their own ASP rates in the quarterly file — billing J0878 for a Hospira vial (or vice versa) is a wrong-code claim, not a rounding difference.

Dose, units & JW/JZ vial math FDA label verified Jul 2026

J0878 is billed at 1 unit = 1 mg on actual body weight. Because daptomycin ships only in 350 mg and 500 mg single-dose vials, almost every real-world dose leaves some drug to discard-report.

FDA-labeled and common off-label dosing

Worked example — 6 mg/kg bacteremia dose, 70 kg patient

NDC reference NDCs verified vs the CMS NDC-HCPCS crosswalk, Jul 2026

Multiple generic manufacturers, both vial sizes represented. Every NDC in this table maps to J0878 at 1 mg per unit per the CMS crosswalk — Hospira/Pfizer, Xellia, and Baxter products bill their own codes (see the J-code map above).

Administration codes CPT verified Jul 2026

Daptomycin is a therapeutic (non-chemotherapy) IV antibiotic. It can be infused over 30 minutes or given as a 2-minute IV push — the push option is a distinctive OPAT/home-infusion efficiency feature.

Full code guidance: 96365/96366 · 96374–96376 · all admin CPT references.

Home infusion — the service-code layer

When daptomycin is delivered through a home-infusion or OPAT program, the drug J-code stays on the home-infusion pharmacy’s claim, while the per-diem service or per-visit professional code is billed separately by the home-infusion provider. Commercial/Medicaid plans use the home-infusion antibiotic S-code family: S9494 is the umbrella total-per-diem code, with frequency-specific per-diem codes alongside it (e.g., S9500 for every-24-hour dosing — the typical daptomycin cadence; S9497/S9501/S9502 for q3h/q12h/q8h regimens). Medicare’s Home Infusion Therapy benefit (effective 2021) uses G-codes G0068/G0069/G0070 by drug category. See the IV antibiotics reference for the full S-code/G-code table across dosing frequencies.

Modifiers CMS verified Jul 2026

JW / JZ — single-dose vial waste reporting

Per CMS’s July 2023 single-dose-container policy (CR 12056), every J0878 claim needs exactly one of JZ (no discard) or JW (discard). Daptomycin ships only in 350 mg and 500 mg single-dose vials, so the modifier always applies. Because weight-based doses rarely match a whole vial exactly, JW is the common case:

Modifier 25 — same-day E/M

Append modifier 25 to the office/clinic E/M (99202–99215) when a significant, separately identifiable evaluation and management service is performed the same day as the infusion — common at OPAT initiation (ID consult-style visit), when interpreting a weekly CPK result that changes the plan, or when assessing a step-down-to-oral decision. A routine pre-infusion check is bundled into the encounter.

340B modifiers (JG, TB) & KX

For 340B-acquired daptomycin at eligible covered entities, follow your MAC’s current 340B modifier policy (JG or TB as directed). Some payers require KX to attest that off-label higher-mg/kg dosing meets the plan’s documented medical-necessity criteria — check the policy before submitting.

ICD-10-CM by indication FY2026 · verified Jul 2026

The diagnosis must support an FDA-labeled or guideline-recognized indication -- never pneumonia, which daptomycin does not treat. Pair with the organism-specific B95–B96 code where known.

Site of care & OPAT Verified Jul 2026

Once-daily dosing and the option to give daptomycin as a 2-minute IV push (no pump required) make it one of the most OPAT-friendly IV antibiotics on the market -- a genuine workhorse for outpatient parenteral antibiotic therapy programs bridging inpatient discharge to a completed course of bacteremia, endocarditis, or osteomyelitis treatment.

Claim form field mapping CMS verified Jul 2026

Office/HOPD daptomycin is a CMS-1500 (837P) or UB-04 (837I) claim. OPAT/home infusion splits into a drug claim and a separate service claim.

Payer policy snapshot Reviewed Jul 2026 · verify current policy

Daptomycin is broadly covered for its FDA-labeled indications; PA scrutiny concentrates on off-label high-dose use, OPAT course length, and CPK monitoring documentation.

Why daptomycin sees lighter PA scrutiny than newer IV antibiotics

Because daptomycin is generic and inexpensive on ASP, payers generally don't apply the same aggressive step-therapy edits used for newer, high-cost agents (ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol) or the single-dose lipoglycopeptides (dalbavancin, oritavancin). The scrutiny that does exist concentrates on course length for OPAT (courses beyond ~14 days commonly need re-authorization) and on off-label dosing above the labeled 4/6 mg/kg, where the payer wants to see the IDSA or equivalent guideline citation.

No drug-specific coverage article found

As of this review, no MAC lists daptomycin on a Self-Administered Drug (SAD) exclusion list, and no drug-specific Local Coverage Determination (LCD) or coverage article was found for daptomycin. Coverage runs through the standard Medicare Part B drug framework -- confirm current MAC policy before assuming this is permanent, since coverage articles can be added.

Medicare reimbursement — J0878 reimbursement (2026) CMS ASP verified Q2 2026

J0878 is an ASP-priced Part B drug. At the current ASP, daptomycin is one of the least expensive drugs on this site -- Medicare pays ASP+6% (subject to ~2% sequestration), and the patient's 20% coinsurance is typically a few dollars per dose.

Coverage

There is no daptomycin-specific NCD; coverage runs through the standard Medicare Part B drug framework for FDA-approved indications. No SAD-list exclusion and no drug-specific LCD/article were identified for daptomycin as of this review.

Code history

• J0878 — permanent HCPCS, "Injection, daptomycin, 1 mg." Applies to brand Cubicin/Cubicin RF and the ANDA generic NDCs.
• J0877 / J0872–J0874 — live manufacturer-specific daptomycin codes (Hospira/Pfizer, Xellia, Baxter), each separately priced in the quarterly ASP file and not therapeutically equivalent to J0878. Match the code to the NDC purchased.

Patient assistance Verified Jul 2026

Daptomycin is the rare drug on this site where the honest answer is: there isn't a copay-assistance program to look for, and there usually doesn't need to be one. Because every currently ASP-priced NDC is generic, the drug cost itself is a few cents per mg -- the worked examples above show a typical bacteremia dose costing roughly $18 in allowed drug charges, with a ~20% Medicare coinsurance around $3.60.

• No manufacturer copay card. Merck's prior patient-support program for Cubicin (Merck Helps) is closed as of this review (verified July 2026 at merckhelps.com). There is no active manufacturer assistance program for daptomycin.
• Generic cost-sharing programs — standard hospital/practice financial-assistance policies and, where applicable, 340B pricing for eligible covered entities are the relevant cost levers, not a branded copay card.
• Foundation copay funds for infectious-disease indications are uncommon and not the primary relief mechanism here, given how low the underlying drug cost already is.
• Where cost actually shows up: the OPAT/home-infusion service charges (nursing, supplies, PICC line placement, per-diem S-codes) typically dwarf the drug cost itself -- that's where a patient's true out-of-pocket exposure and any financial-assistance conversation should focus.

Common denials & how to fix them Reviewed Jul 2026

Frequently asked questions

What is the HCPCS J-code for Cubicin (daptomycin)?

Most daptomycin NDCs — brand Cubicin and the ANDA generics — are billed under HCPCS J0878, defined as "Injection, daptomycin, 1 mg." One billed unit = 1 mg, so a 420 mg dose is J0878 × 420. But not every daptomycin product bills J0878: CMS maintains live manufacturer-specific codes that are NOT therapeutically equivalent to J0878 — Hospira/Pfizer daptomycin bills J0877, and the Xellia and Baxter products bill J0872/J0873 and J0874 respectively, each priced separately in the CMS ASP file. Match the J-code to the NDC actually purchased using the CMS NDC-HCPCS crosswalk before building the claim.

How do I bill Cubicin vial waste with JW and JZ?

Daptomycin is supplied in 350 mg and 500 mg single-dose vials, so every claim needs exactly one of JZ (no discard) or JW (discard) per CMS CR 12056. Example: a 420 mg dose (6 mg/kg for a 70 kg patient) drawn from one 500 mg vial leaves 80 mg discarded -- bill J0878 × 420 on the administered line with no waste modifier, plus a separate J0878 line with modifier JW × 80 for the discard. Never add JZ to the administered line when a JW line exists for the same date of service — JW and JZ are mutually exclusive on the same drug, same day. Use JZ alone only when the full vial (or vial combination) is used with zero discard.

What is the daptomycin dose for MRSA bacteremia versus skin infections?

FDA-labeled dosing is indication-specific and calculated on actual body weight: complicated skin and skin-structure infections (cSSSI) are dosed at 4 mg/kg IV once every 24 hours, while Staphylococcus aureus bloodstream infection (bacteremia), including right-sided infective endocarditis, is dosed at 6 mg/kg IV once every 24 hours. Higher doses of 8–10 mg/kg are used off-label, guideline-supported by IDSA, for persistent/salvage MRSA bacteremia, complicated endocarditis, vancomycin-resistant Enterococcus (VRE), and osteomyelitis -- document the guideline citation and the weight-based calculation on the prior-authorization request for any off-label dose.

Why can't daptomycin be used for pneumonia?

Daptomycin is not FDA-approved for pneumonia of any kind and should not be used to treat it. Pulmonary surfactant binds and inactivates daptomycin, so it does not achieve adequate concentrations in lung tissue and has shown inferior outcomes in respiratory infections in clinical trials. This is a hard clinical and coverage limitation, not a dosing question -- a pneumonia diagnosis code paired with a daptomycin claim is a medical-necessity red flag for both the treating clinician and the payer.

Does Cubicin (daptomycin) have a manufacturer copay card?

No. Daptomycin is generic -- every NDC currently priced in the CMS ASP file is from a generic manufacturer (Hikma, Accord, Sagent, Dr. Reddy’s, Apotex, Viatris and others), and Merck's branded Cubicin RF does not appear in the current ASP file. Merck's patient support program for Cubicin (Merck Helps) is closed as of this review. There is no daptomycin copay card to look for -- the practical cost story is that the drug itself is inexpensive (ASP of a few cents per mg), so even Medicare's 20% coinsurance on a typical dose is a few dollars, not a few hundred.

What lab monitoring does daptomycin require, and does it affect billing?

Daptomycin carries a risk of skeletal-muscle toxicity, so the label calls for baseline creatine phosphokinase (CPK) and weekly CPK monitoring during therapy, with more frequent checks if the patient is on a concomitant statin, has renal impairment, or reports myalgia/weakness. CPK labs are billed separately from the drug and administration codes (not bundled into J0878), but the monitoring plan is exactly what payers look for in OPAT prior-authorization documentation and in post-payment chart audits for extended courses.

How is the daptomycin dose adjusted for kidney disease?

For patients with CrCl <30 mL/min, including those on hemodialysis, the FDA label extends the dosing interval to every 48 hours at the same indication-appropriate mg/kg -- it is a frequency adjustment, not a per-dose mg reduction. Document renal function and the adjusted interval in the chart; billing the standard every-24-hour frequency for a patient documented with severe renal impairment can trigger a chart-audit flag even though the per-dose unit count doesn’t change.

Source documents

1. DailyMed — Daptomycin (Cubicin) prescribing information
   Current FDA label; indications, mg/kg dosing, renal adjustment, CPK monitoring, pneumonia limitation
2. CMS HCPCS Level II — J0878
   "Injection, daptomycin, 1 mg"; applies to brand and every generic manufacturer's NDC
3. CMS — Medicare Part B Drug ASP Pricing File
   Quarterly ASP+6% pricing; J0878 = $0.034/mg (Q2 2026), live-bound on this page
4. CMS — JW/JZ modifier policy (CR 12056, eff. July 2023)
   Single-dose-container discard reporting; applies to daptomycin's 350/500 mg single-dose vials
5. FDA National Drug Code Directory — daptomycin NDCs
   Verify the 11-digit NDC for the exact vial/manufacturer used
6. AMA CPT — therapeutic IV infusion/push codes (96365, 96366, 96374, 96375)
   Administration coding for infusion vs push; not chemotherapy administration
7. Infectious Diseases Society of America (IDSA) — MRSA and OPAT clinical practice guidelines
   Off-label high-dose bacteremia/endocarditis regimens; OPAT documentation elements (ID consult, access plan, monitoring, step-down)
8. CMS — ICD-10-CM (FY2026)
   A41.x bacteremia/sepsis; I33.0 endocarditis; L02.x/L03.x skin infections; M86.x osteomyelitis
9. Merck Helps (patient assistance)
   Prior Cubicin patient-support program; confirmed closed as of this review (July 2026)
10. CMS Medicare Coverage Database
    Searched for daptomycin-specific NCD/LCD/coverage article and SAD-list entries; none found as of this review

About this page

We maintain this page as a living reference for billers, coders, and revenue-cycle staff working with daptomycin claims in infectious disease, hospital medicine, and OPAT/home-infusion programs. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes. The J0878 ASP figure is live-bound to the CareCost CMS ASP layer, so the per-mg price reflects the current quarter automatically.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• Jul 14, 2026 — Blind QA review pass: corrected the J-code map to flag the live manufacturer-specific daptomycin codes (J0877 Hospira/Pfizer, J0872/J0873 Xellia, J0874 Baxter — separately priced, not therapeutically equivalent to J0878); updated the vancomycin cross-reference to J3373 (J3370 deleted June 30, 2025); corrected NDC 16714-0892-01 labeler to NorthStar Rx; corrected the home-infusion S-code frequencies (S9494 = umbrella total diem, S9500 = q24h); replaced CPT descriptor text with original paraphrases; aligned per-mg cost phrasing with the current ASP.
• Jul 14, 2026 — Initial publication. Daptomycin (Cubicin) billing reference: J0878 at 1 mg/unit with live ASP binding; brand-vs-generic same-J-code clarification; 350/500 mg single-dose vial JW/JZ discard math with worked mg/kg examples; therapeutic IV infusion/push admin codes; FDA-label vs off-label (IDSA) dosing; weekly CPK monitoring; OPAT/home-infusion site-of-care; pneumonia-limitation warning; confirmed no manufacturer copay program.

Methodology

Every claim on this page is sourced inline. Dosing, indications, monitoring requirements, and the pneumonia limitation are taken from the current FDA prescribing information; the ASP figure is read live from the CMS Part B ASP file; administration codes are from AMA CPT; off-label dosing guidance follows published IDSA practice guidelines. We do not paraphrase from billing-software vendor blogs, and we flag anything not yet SME-verified rather than assert it.